Browse > Article

Concurrent Docetaxel/Cisplatin and Thoracic Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer  

Jang, Tae Won (Department of Internal Medicine, Kosin University College of Medicine)
Park, Jung Pil (Department of Internal Medicine, Kosin University College of Medicine)
Kim, Hee Kyoo (Department of Internal Medicine, Kosin University College of Medicine)
Ok, Chul Ho (Department of Internal Medicine, Kosin University College of Medicine)
Jeung, Tae Sig (Department of Radiotherapy, Kosin University College of Medicine)
Jung, Maan Hong (Department of Internal Medicine, Kosin University College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.57, no.3, 2004 , pp. 257-264 More about this Journal
Abstract
Background : There are many combinations of treatment for locally advanced non-small cell lung cancer (NSCLC). Recent studies have showed the efficacy of concurrent chemoradiotherapy (CCRT) in NSCLC. At present, however, there is no consensus about the optimal dosages and timing of radiation and chemotherapeutic agents. The aims of study were to determine the feasibility, toxicity, response rate, and survival rate in locally advanced NSCLC patients treated with doxetaxel and cisplatin based CCRT. Method : Sixteen patients with unresectable stage III NSCLC were evaluated from May 2000 until September 2001. Induction chemoradiotherapy consisted of 3 cycles of docetaxel (75 $mg/m^2/IV$ on day 1) and cisplatin (60 $mg/m^2/IV$ on day 1) chemotherapy every 3 weeks and concomitant hyperfractionated chest irradiation (1.15 Gy/BID, total dose of 69 Gy) in 6 weeks. Patient who had complete or partial response, and stable disease were applied consolidation chemotherapy of docetaxel and cisplatin. Results : All patients showed response to CCRT. Four patients achieved complete response (25%), partial responses in 12 patients (75%). The major common toxicities were grade III or more of neutropenia (87.3%), grade III esophagitis (68.8%), pneumonia (18.8%) and grade III radiation pneumonitis (12.5%). Thirteen patients were ceased during follow-up period. Median survival time was 19.9 months (95% CI; 4.3-39.7 months). The survival rates in one, two, and three years are 68.7%, 43.7%, and 29.1%, respectively. Local recurrence was found in 11 patients (66.8%), bone metastasis in 2, and brain metastasis in 1 patient. Conclusion : The response rate and survival time of CCRT with docetaxel/cisplatin in locally advanced NSCLC were encouraging, but treatment related toxicities were high. Further modification of therapy seems to be warranted.
Keywords
Non-small cell lung cancer; Locally advanced; Concurrent chemoradiotherapy;
Citations & Related Records

Times Cited By SCOPUS : 1
연도 인용수 순위
1 Le Chevalier T, Arriagata R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis ofa randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-23
2 Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. Cancer 1995;76:593􀁔601
3 Sause W, Kolesar P, Taylor S, Johnson D, Livingston R, Komaki R, et al. Final Results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 2000;117:358-64
4 Furuse K, Kawahara M, Fukuoka M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesin and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17:2692-9
5 Chung HC, Choi JH, Rho JK, Kim SK, Lee WY, Kim GE: Phase II trial of sequential VP-16, cisplatin combination chemotherapy and radiotherapy for locally advanced (stageIII) non small cell lung cancer. J Korean Cancer Assoc 1991;23(3):131-9
6 Jett JR, Scott WJ, Rivera MP, Sause WT. Guidelines on treatment of stage IIIB non􀁔small cell lung cancer. Chest 2003;123:221-5
7 Wu HG, Bang YJ, Choi EK, Ahn YC, Kim YW, Lim TH, et al. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:75-80
8 Janne PA, Skarin AT. Concurrent docetaxel and thoracic radiation in non-small cell lung cancer. Clinical Lung Cancer 2002;3(2):S37-S41
9 Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM. Factors affecting the risk of brain metastasis after definitive chemoradiation for locally advanced non-small cell lung cancer. J Clin Oncol 2001;19(5):1344-9
10 Choy H, Curran WJ, Scott CB, Bonomi P, Travis P, Haluschak J, Belani CP. Preliminary report of locally advanced multimodality protocol (LAMP).Proc Am Soc Clin Oncol 2002;1160
11 Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. A meta-analysis. Ann Intern Med 1996;125:723-29
12 Kim SY. Treatment of Lung Cancer. Korean Academy of Tuberculosis and Respiratory Dieases. Respiratory Diseases. Seoul: Koonja; 2004. p. 621-9
13 Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990;323:940-5
14 Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP. Combination chemotherapy and crossresistance studies with tumors of mice. CancerTreat Report 1979;63(2):1459-73
15 Arriagada R, Le Chevalier T, Quoix E, Ruffie P, de Cremoux H, Doulliard JY, et al. Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1991:20:1183-90
16 WHO recommendations for grading of acute and subacute toxicity: reporting the results of cancer treatment. Cancer 1981;47:207-14
17 Milas L. Docetaxel/radiation combinations: rationale and preclinical findings. Clin Lung Cancer 2002;3:S29-36
18 Law A, Karp DD, Dipetrillo T, Daly BT. Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy inpatients with locally advanced non-small cell lung cancer. Cancer 2001;92:160-4
19 Kim TE, Murren JR. Therapy for stage IIIb and stage IV non-small cell lung cancer. Clin Chest Med 2002;23:209-24
20 Robinson LA, Wagner H Jr., Ruckdeschel JC. Treatment of stage IIIA non-small cell lung cancer. Chest 2003;123:202S-20S
21 Lee SW, Choi EY, Oh SJ, Suh CW, Kim SW, Lee JS, Kim DS, Kim WD, Lee SD, Kim JH, Kim GJ, Noh YJ. Preliminary results of paclitaxel, cisplatin, and concurrent high-dose radiation therapy for locally advanced non-small-cell lung cancer. Cancer Research and Treatment 2002;34:345-51
22 Ministry of Health and Welfare. Annual report of cancer registry program in the Republic of Korea; 2002
23 Gandara DR, Lara PN, Goldbergz Lau DH. Integration of new chemotherapeutic agents into chemoradio therapy for stage III non-small cell lung cancer, Semin Oncol 2001;28:26-32
24 Gandara DR, Lara PN Jr, Goldbergz Lau DH. Integration of new chemotherapeutic agents into chemoradio therapy for stage III non-small cellcancer. Semin Oncol 2001;28:26-32
25 Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIb non-small-cell lung cancer. J Clin Oncol 2003;21:2004-10
26 Sause W, Kolesar P, Tayer S, Johnson D, Livinston R, Komaki R, Emami B, Curran W jr, Byhardt R, Dar AR, Turrisi A 3rd. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 2000;117:358-64
27 Scientific committee of Korean academy of tuberculosis and respiratory Diseases: The national survey of lung cancer in Korea. Tuberculosis and Respiratory Diseases 1999;46:455-65